Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acsé Program

This article has no abstract
Epistemonikos ID: 4cdf3b569666a16df77f721b980855b65e28b900
First added on: Feb 06, 2025